Street Calls of the Week
WALTHAM, Mass. - OptimizeRx Corp. (NASDAQ:OPRX), which has seen its stock surge over 249% year-to-date according to InvestingPro data, announced Tuesday a series of leadership changes designed to accelerate the company’s "Rule of 40" strategy, which aims to balance sustained growth with increased profitability over the next 2-3 years.
The healthcare technology company, which helps life sciences companies connect with healthcare professionals and patients, has appointed Ed Stelmakh as Chief Financial & Strategic Officer, expanding his role to include broader corporate strategy alongside financial leadership.
Other leadership changes include Brendan Merrell’s promotion to Chief Operating Officer from his previous role as SVP of Client Strategy & Program Management, and Andy D’Silva’s advancement to Chief Business Officer from SVP of Corporate Finance.
Theresa Greco will continue as Chief Commercial Officer focusing on the company’s growth plan and transition to a recurring revenue model. Marion Odence-Ford has been named Chief Legal & Administrative Officer with expanded responsibilities, while Doug Besch will continue as Chief Product & Technology Officer.
"Over the past six months, I have had the opportunity to evaluate our organization from the CEO seat and make key decisions to ensure we are positioned to execute with focus, speed, and strategic clarity," said Steve Silvestro, Chief Executive Officer of OptimizeRx.
The reorganization reflects the company’s focus on profitable growth and developing internal talent to drive its strategic objectives. According to the company’s statement, these leadership advancements are designed to help OptimizeRx achieve its Rule of 40 targets while creating a more predictable financial profile.
Based in Waltham, Massachusetts, OptimizeRx provides technology solutions that connect pharmaceutical companies with healthcare providers and patients through its omnichannel network.
The information in this article is based on a press release issued by OptimizeRx.
In other recent news, OptimizeRX has reported impressive financial results for the second quarter of 2025. The company achieved revenue of $29.2 million, marking a 55% increase compared to the same period last year. This figure significantly surpassed both JMP Securities’ estimate of $22.2 million and the consensus expectation of $22.3 million. Additionally, OptimizeRX delivered an earnings per share (EPS) of $0.24, far exceeding the forecasted $0.02, resulting in an astounding 1100% surprise. These strong earnings prompted JMP Securities to raise its price target for OptimizeRX from $14.00 to $20.00, while maintaining a Market Outperform rating. This adjustment reflects the firm’s positive outlook on the company’s financial health. The reported results highlight OptimizeRX’s ability to outperform analyst predictions and strengthen investor confidence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.